RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a WeekZacks Investment Research • 10/15/26
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?Zacks Investment Research • 10/14/26
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 MillionGlobeNewsWire • 10/14/26
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost CashZacks Investment Research • 10/08/26
Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 millionProactive Investors • 10/07/26
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 MillionGlobeNewsWire • 10/07/26
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREGlobeNewsWire • 10/06/26
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA ValidationZacks Investment Research • 10/05/26
Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)GlobeNewsWire • 10/02/26
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene TherapyZacks Investment Research • 09/18/26
Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?Zacks Investment Research • 09/18/26
Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of FAYUVI as First Treatment for Sanfilippo Syndrome Type A TranscriptSeeking Alpha • 09/18/26
How This Gene Therapy Name Partially Reversed Its Catastrophic 44% DiveInvestors Business Daily • 09/17/26
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)GlobeNewsWire • 09/17/26
RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses GoalsZacks Investment Research • 09/03/26
Ultragenyx's 'Fall From Grace' — Shares Crash 47%, Hitting A Record LowInvestors Business Daily • 09/03/26
Ultragenyx Stock Sinks 47% on Drug Trial Failure. Why Wall Street Isn't Giving Up Yet.Barrons • 09/03/26
Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic DiseaseGlobeNewsWire • 09/01/26